Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with the Argentinian company Tuteur. As part of this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for the treatment of autoimmune diseases throughout Latin America (LATAM), with the exception of Brazil.

Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tutor will be responsible for marketing, marketing and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biologic treatments across the region.

"Our partnership with Tuteur represents an important step in our mission to expand access to biosimilars globally," said Anjan Selz, Chief Executive Officer of Polpharma Biologics. "With their strong regional expertise and commercial capabilities in Latin America, we are well positioned to bring this important treatment to patients with autoimmune diseases. Together, we aim to improve access to effective and affordable treatment options across the region. »

"Our collaboration with Polpharma Biologics marks an important milestone for Tuteur," said Jonathan Hahn, President of Tuteur. "Our partnership with an organization of this caliber reinforces our commitment to expanding access to world-class biologics for patients across Latin America."

This biosimilar is currently under development and is designed to provide an effective and well-tolerated treatment option for patients with autoimmune diseases. The submission of the regulatory file is planned for the next three years.